Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Sree M Lanka"'
Publikováno v:
Current Oncology, Vol 30, Iss 4, Pp 4246-4256 (2023)
The therapeutic landscape of several genitourinary malignancies has been revolutionized by the development of immune checkpoint inhibitors (ICIs); however, the utility of immunotherapies in prostate cancer has been limited, partly due to the immunolo
Externí odkaz:
https://doaj.org/article/52d8e5ded7684469971dc8a5c6e36a6f
Autor:
Albert Jang, Sree M. Lanka, Minqi Huang, Crystal V. Casado, Sydney A. Caputo, Patrick L. Sweeney, Kanika Gupta, Olivia Pocha, Nicholas Habibian, Madeline E. Hawkins, Alexandra D. Lieberman, Jennifer Schwartz, Ellen B. Jaeger, Patrick J. Miller, Jodi L. Layton, Pedro C. Barata, Brian E. Lewis, Elisa M. Ledet, Oliver Sartor
Publikováno v:
The Prostate.
Autor:
Crystal Casado, Sydney Caputo, Ellen B. Jaeger, Albert Jang, Patrick L Sweeney, Sree M Lanka, Kanika Gupta, Olivia Pocha, Maddie Hawkins, Minqi Huang, Alexandra Lieberman, Jennifer Schwartz, Patrick Miller, Pedro C. Barata, Jodi Lyn Layton, Brian E. Lewis, Elisa M. Ledet, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:248-248
248 Background: mCRPC patients with liver metastases have a poor prognosis and often progress rapidly on a variety of treatments. Previously, preliminary ctDNA analyses of mCRPC patients with liver metastases showed a range of commonly altered genes
Autor:
Kanika Gupta, Sydney Caputo, Crystal Casado, Albert Jang, Patrick L Sweeney, Sree M Lanka, Olivia Pocha, Maddie Hawkins, Alexandra Lieberman, Jennifer Schwartz, Patrick Miller, Ellen B. Jaeger, Pedro C. Barata, Jodi Lyn Layton, Brian E. Lewis, Elisa M. Ledet, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:230-230
230 Background: Somatic alterations change over time in response to treatment and disease progression in patients with prostate cancer (PCa). We report ctDNA findings of patients who died from PCa within 3 months of a ctDNA assessment to better chara
Autor:
Sree M Lanka, Albert Jang, Patrick L Sweeney, Kanika Gupta, Sydney Caputo, Crystal Casado, Minqi Huang, Olivia Pocha, Maddie Hawkins, Alexandra Lieberman, Jennifer Schwartz, Ellen B. Jaeger, Patrick Miller, Jodi Lyn Layton, Pedro C. Barata, Brian E. Lewis, Elisa M. Ledet, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:243-243
243 Background: Lutetium-177- PSMA-617 (Lu-177) is a radioligand therapy that delivers radiation to PSMA-expressing cells in patients with advanced prostate cancer. In this study, we aimed to analyze ctDNA in responders and non-responders after Lu-17
Autor:
Albert Jang, Minqi Huang, Crystal Casado, Sydney Caputo, Patrick L Sweeney, Sree M Lanka, Kanika Gupta, Olivia Pocha, Nicholas Habibian, Maddie Hawkins, Alexandra Lieberman, Jennifer Schwartz, Ellen B. Jaeger, Patrick Miller, Jodi Lyn Layton, Pedro C. Barata, Brian E. Lewis, Elisa M. Ledet, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:35-35
35 Background: Genetic differences between African American and Caucasian patients with advanced prostate cancer may contribute to racial disparities in terms of treatment outcomes and survival, hence further exploration is warranted. We assessed ctD
Autor:
Minqi Huang, Ellen B. Jaeger, Sydney Caputo, Crystal Casado, Albert Jang, Patrick L Sweeney, Sree M Lanka, Kanika Gupta, Alexandra Lieberman, Jennifer Schwartz, Olivia Pocha, Maddie Hawkins, Patrick Miller, Jodi Lyn Layton, Brian E. Lewis, Pedro C. Barata, Elisa M. Ledet, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:253-253
253 Background: Approximately 3-5% of advanced prostate cancer patients have pathogenic BRCA2 mutations in germline tests. In this study, we examine the relationship between pathogenic germline BRCA2 mutation and somatic changes in ctDNA. Methods: Ge
Autor:
Albert Jang, Ellen B. Jaeger, Grant Rauterkus, Alexandra Lieberman, Minqi Huang, Sree M Lanka, Sumedha Sudhaman, Tamara Mahmood, Natalia Pajak, Mark Calhoun, Kaoutar Tlemcani, Adam ElNaggar, Minetta Liu, Brian E. Lewis, Jodi Lyn Layton, A. Oliver Sartor, Pedro C. Barata
Publikováno v:
Journal of Clinical Oncology. 41:721-721
721 Background: Current methodologies for monitoring treatment response are largely based on conventional scans and/or tumor biopsies, which may be limited in their ability to accurately assess disease burden at the molecular level. Circulating tumor